AMAG Pharmaceuticals (AMAG)

AMAG Pharmaceuticals Inc. (AMAG - Snapshot Report) develops superparamagnetic iron oxide nanoparticles for use in pharmaceutical products. The company's focus is on developing IV iron replacement therapy for anemia in chronic kidney disease and imaging agent to aid in diagnosis.

The company filed the NDA for its lead drug Feraheme in December 2007, and the drug was approved by the FDA on June 30, 2009. Clinical data in over 1,700 patients indicate an excellent safety profile for the drug with lower incidents of heart problems.

Clinical results and eventual approval for additional indications should ensure strong growth in the coming years. We maintain our Buy rating on the shares of AMAG with a target price of $62.

AMAG Pharmaceuticals (AMAG) : FULL ANALYST REPORT

Email	Print	Share	RSS	Rate Pos	Rate Neg	Comment

Loading Stories...

Related Content

RELATED ARTICLES BULL OF THE DAY ARCHIVE

Zacks Equity Research: Report For ADMG
N/A	02/04/10
Zacks Blog: AMAG Pharma Guides on Feraheme
(AMAG, SSRX)	01/11/10
Zacks Blog: AMAG Pharma’s Feraheme Holds Promise
(AMAG, WPI, FMS, SNY)	07/30/09
Zacks Blog: Zacks Analyst Blog Highlights: AMAG Pharmaceuticals Inc., Fresenius Medical Care AG & Co., Watson Pharmaceuticals, Inc., Sanofi-Aventis and ReneSola Ltd.
(AMAG, FMS, WPI, SNY, SOL)	07/15/09
Zacks Blog: AMAG Kidney Drug Launched
(AMAG, FMS, WPI, SNY)	07/14/09

 Posting Comment...

There was a problem posting this this comment. Please try back later.
[CLICK TO CLOSE X]

Comments (Limit 1000 Characters - Used: 0)

Please provide your comments here... Display Name: Email Address:  

 Loading Comments...

Be the first to comment on this article!